Woodline Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Woodline Partners’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.11M	Hold	195,033	–	–	0.02%	687
2026 Q1	$4.59M	Hold	195,033	–	–	0.02%	673
2025 Q4	$5.66M	Sell	195,033 -119,586	-38%	-$3.06M	0.02%	599
2025 Q3	$5.93M	Buy	314,619 +109,109	+53%	+$1.72M	0.03%	536
2025 Q2	$2.88M	Sell	205,510 -204,490	-50%	-$2.87M	0.02%	665
2025 Q1	$6.41M	Buy	+410,000	New	+$5.78M	0.04%	444
2023 Q4	–	Sell	-1,104,244	Closed	-$5.86M	–	483
2023 Q3	$5.86M	Buy	1,104,244 +296,494	+37%	+$2.52M	0.07%	298
2023 Q2	$7.7M	Buy	807,750 +112,075	+16%	+$1.24M	0.09%	241
2023 Q1	$7.65M	Buy	695,675 +50,776	+8%	+$735K	0.1%	236
2022 Q4	$9.54M	Buy	644,899 +94,503	+17%	+$1.65M	0.13%	219
2022 Q3	$10.5M	Buy	+550,396	New	+$12.5M	0.15%	195

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Woodline Partners's ARQT Position: Q2 2026 in Review

Woodline Partners held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 195,033 shares worth $5.11M. The position accounts for 0.02% of the portfolio, ranked #687.

Woodline Partners first reported a position in ARQT in Q3 2022 and has held it in 11 quarters since. The position peaked at $10.5M in Q3 2022. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Woodline Partners held 195,033 shares of Arcutis Biotherapeutics worth $5.11M as of Q2 2026.
Woodline Partners left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #687 holding.
Woodline Partners first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 11 quarters since.
Woodline Partners's Arcutis Biotherapeutics position peaked at $10.5M in Q3 2022.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.